



CrossMark

**“Number needed to treat: enigmatic results for exacerbations in COPD.”**  
Samy Suissa. *Eur Respir J* 2015; 45: 875–878.

This article from the April 2015 issue of the *European Respiratory Journal* was originally published with an error in table 2. The COPD exacerbations rate per patient per year for each of the two treatment columns (fluticasone/salmeterol and placebo) had been transposed in error. The corrected table is presented below, and the original article has been corrected and republished online.

TABLE 2 NNT to prevent a COPD exacerbation over 1 year of treatment with fluticasone/salmeterol compared with placebo, for each of the 3 years of follow-up in the TORCH trial [4]

Year of follow-up	COPD exacerbations per patient per year		NNT
	Fluticasone/salmeterol	Placebo	
<b>1</b>	2.4	4.5	0.5
<b>2</b>	1.3	1.6	3
<b>3</b>	1.0	1.2	5

NNT: number needed to treat; COPD: chronic obstructive pulmonary disease; TORCH: Towards a Revolution in COPD Health.

Copyright ©ERS 2018